Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
6 - Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
Published online by Cambridge University Press: 19 October 2021
Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
Summary
Many nonchemotherapy medications are associated with neutropenia risk, but it was the cluster of 16 severe clozapine-related neutropenia cases reported from Finland in mid-summer 1975 with a 50% fatality rate that prompted clozapine’s withdrawal. Clozapine was subsequently reintroduced to the world market in the late 1980s based on demonstrable efficacy in treatment-resistant schizophrenia, albeit with mandatory hematologic monitoring and patient tracking.
- Type
- Chapter
- Information
- The Clozapine HandbookStahl's Handbooks, pp. 114 - 139Publisher: Cambridge University PressPrint publication year: 2019
References
Curtis, B. R. (2017). Non-chemotherapy drug-induced neutropenia: Key points to manage the challenges. ASH Hematology, The Education Program, 2017, 187–193.CrossRefGoogle ScholarPubMed
Amsler, H. A., Teerenhovi, L., Barth, E., et al. (1977). Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatrica Scandinavica, 56, 241–248.Google Scholar
Nielsen, J., Young, C., Ifteni, P., et al. (2016). Worldwide differences in regulations of clozapine use. CNS Drugs, 30, 149–161.Google Scholar
Myles, N., Myles, H., Xia, S., et al. (2018). Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatrica Scandinavica, 138, 101–109.Google Scholar
Honigfeld, G., Arellano, F., Sethi, J., et al. (1998). Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. Journal of Clinical Psychiatry, 59(Suppl 3), 3–7.Google ScholarPubMed
Sultan, R. S., Olfson, M., Correll, C. U., et al. (2017). Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. Journal of Clinical Psychiatry, 78, e933–e939.CrossRefGoogle ScholarPubMed
Broun, G. O., Herbig, F. K. and Hamilton, J. R. (1966). Leukopenia in Negroes. New England Journal of Medicine, 275, 1410–1413.CrossRefGoogle ScholarPubMed
Paz, E., Bouzas, L., Hermida, J., et al. (2008). Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clinical Biochemistry, 41, 603–606.CrossRefGoogle ScholarPubMed
Schmid, P., Ravenell, K. R., Sheldon, S. L., et al. (2012). DARC alleles and Duffy phenotypes in African Americans. Transfusion, 52, 1260–1267.CrossRefGoogle ScholarPubMed
Paz, Z., Nails, M. and Ziv, E. (2011). The genetics of benign neutropenia. Israel Medical Association Journal, 13, 625–629.Google ScholarPubMed
Ortiz, M. V., Meier, E. R. and Hsieh, M. M. (2016). Identification and clinical characterization of children with benign ethnic neutropenia. Journal of Pediatric Hematology and Oncology, 38, e140–143.CrossRefGoogle ScholarPubMed
Reich, D., Nalls, M. A., Kao, W. H., et al. (2009). Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genetics, 5, e1000360.Google Scholar
Dinardo, C. L., Kerbauy, M. N., Santos, T. C., et al. (2017). Duffy null genotype or Fy(a–b–) phenotype are more accurate than self-declared race for diagnosing benign ethnic neutropenia in Brazilian population. International Journal of Laboratory Hematology, 39, e144–e146.CrossRefGoogle ScholarPubMed
Denic, S., Showqi, S., Klein, C., et al. (2009). Prevalence, phenotype and inheritance of benign neutropenia in Arabs. BMC Blood Disorders, 9, 3.Google ScholarPubMed
Kelly, D. L., Kreyenbuhl, J., Dixon, L., et al. (2007). Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophrenia Bulletin, 33, 1221–1224.CrossRefGoogle ScholarPubMed
Bartels, M., van Solinge, W. W., den Breeijen, H. J., et al. (2012). Valproic acid treatment is associated with altered leukocyte subset development. Journal of Clinical Psychopharmacology, 32, 832–834.CrossRefGoogle ScholarPubMed
Malik, S., Lally, J., Ajnakina, O., et al. (2018). Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research, 195, 267–273.Google Scholar
Demler, T. L., Morabito, N. E., Meyer, C. E., et al. (2016). Maximizing clozapine utilization while minimizing blood dyscrasias: Evaluation of patient demographics and severity of events. International Clinical Psychopharmacology, 31, 76–83.Google Scholar
Goldstein, J. I., Jarskog, L. F., Hilliard, C., et al. (2014). Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 5, 4757.Google Scholar
Legge, S. E., Hamshere, M. L., Ripke, S., et al. (2017). Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry, 22, 1502–1508.Google Scholar
Regen, F., Herzog, I., Hahn, E., et al. (2017). Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicology and Applied Pharmacology, 316, 10–16.CrossRefGoogle ScholarPubMed
Wicinski, M. and Weclewicz, M. M. (2018). Clozapine-induced agranulocytosis/granulocytopenia: Mechanisms and monitoring. Current Opinion in Hematology, 25, 22–28.CrossRefGoogle ScholarPubMed
Focosi, D., Azzara, A., Kast, R. E., et al. (2009). Lithium and hematology: Established and proposed uses. Journal of Leukocyte Biology, 85, 20–28.CrossRefGoogle ScholarPubMed
Ballin, A., Lehman, D., Sirota, P., et al. (1998). Increased number of peripheral blood CD34+ cells in lithium-treated patients. British Journal of Haematology, 100, 219–221.Google Scholar
Myles, N., Myles, H., Clark, S. R., et al. (2017). Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. Australian & New Zealand Journal of Psychiatry, 51, 980–989.CrossRefGoogle ScholarPubMed
Gopalakrishnan, R., Subhalakshmi, T. P., Kuruvilla, A., et al. (2013). Clozapine re-challenge under the cover of filgrastim. Journal of Postgraduate Medicine, 59, 54–55.Google Scholar
Kelly, D. L., Ben-Yoav, H., Payne, G. F., et al. (2018). Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clinical Schizophrenia & Related Psychoses, 12, 23–30.CrossRefGoogle ScholarPubMed
Bui, H. N., Bogers, J. P., Cohen, D., et al. (2016). Evaluation of the performance of a point-of-care method for total and differential white blood cell count in clozapine users. International Journal of Laboratory Hematology, 38, 703–709.Google Scholar
Andersohn, F., Konzen, C. and Garbe, E. (2007). Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Annals of Internal Medicine, 146, 657–665.Google Scholar
Alvir, J. M., Lieberman, J. A., Safferman, A. Z., et al. (1993). Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New England Journal of Medicine, 329, 162–167.Google Scholar
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C. (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition (pp. 279–302). Chicago, IL: McGraw-Hill.Google Scholar
Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: An electronic health record study. Neuropsychopharmacology, 41, 1138–1143.Google Scholar
Andres, E. and Mourot-Cottet, R. (2017). Clozapine-associated neutropenia and agranulocytosis. Journal of Clinical Psychopharmacology, 37, 749–750.CrossRefGoogle ScholarPubMed